A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects With Rheumatoid Arthritis
Phase of Trial: Phase III
Latest Information Update: 19 Aug 2017
At a glance
- Drugs Filgotinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms FINCH 4
- Sponsors Gilead Sciences
- 04 May 2017 Planned End Date changed from 1 Aug 2023 to 1 Jun 2023.
- 27 Sep 2016 Status changed from planning to recruiting, according to Gilead Sciences media release.
- 24 May 2016 According to a Galapagos NV media release, company expected to start dosing of subjects in this trial in Q3 2016.